CDKN2A and cancer: While the cyclin D/CDK4/6/p16INK4a/RB pathway is frequently disrupted in cancer, the majority of human neoplasms maintain functional RB but have aberrations that increase the activity of CDK4/6, which hyper-phosphorylates RB and allows cell proliferation [1, 2].